Revance Therapeutics closes $45M round to advance skin treatments; FDA fast tracks anthrax vaccine;

@FierceBiotech: Pfizer unveils $100M Boston effort to spark R&D innovation. News | Follow @FierceBiotech

@JohnCFierce: Quick shout out to the people who submitted close to 50 Fierce 15 nominations in the first 24 hours. Keep those cards and letters coming! Submission form | Follow @JohnCFierce

> Revance Therapeutics has closed a $45 million financing as the firm advances development of a topical gel form of botulinum toxin type A used to smooth wrinkles in the skin. Release

> The FDA has fast tracked Emergent BioSolutions's Phase I anthrax vaccine, called NuThrax. Emergent release

> Members of North Carolina's Senate Finance committee have once again proposed legislation that would provide funding to biotech start-ups. Critics say the Life Sciences Development Act puts the state in the business of taking on venture capitalists' risk. Report

> Biodefense company PharmAthene plans to sell $6.5 million of its common stock and warrants in a registered direct offering. PharmAthene release

> A novel variant of swine flu has emerged in Asia with a genetic adaptation giving some resistance to Roche's Tamiflu and GlaxoSmithKline's Relenza, the two mainstay drugs used to tackle the disease. Article

Pharma News

@FiercePharma: France suspends Takeda's Actos on cancer data. Item | Follow @FiercePharma

> FTC mulls agency action against pay-for-delay. Article

> UCB to pay $34M for off-label marketing. Story

> Hong Kong yanks GSK drug on phthalate levels. Item

> Germany joins in suspension of Takeda's Actos. Report

Most Popular This Week

> Alzheimer's biomarker market to reach $9B in decade. Item

> Pfizer embarks on a 'first' all-electronic clinical trial. Story

> Roche, Merck to collaborate on cancer diagnostics. Article

> FDA steps in to prevent drug shortages. Report

> Obesity vaccine would suppress hunger hormone. Story

> Cholera molecule helps cocaine addicts kick the habit. Article

> Adult vaccines cut down on healthcare costs. Piece

> Pfizer plots another $1B in cost cuts. Article

> Pfizer unveils $100M Boston effort to spark R&D innovation. Report

And Finally... Orphan diseases are a result of mutations to genes essential to survival, according to research reported in the American Journal of Human Genetics. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.